Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

BET Inhibition Silences Expression of <i>MYCN</i> and <i>BCL2</i> and Induces Cytotoxicity in Neuroblastoma Tumor Models

<div><p>BET family proteins are epigenetic regulators known to control expression of genes involved in cell growth and oncogenesis. Selective inhibitors of BET proteins exhibit potent anti-proliferative activity in a number of hematologic cancer models, in part through suppression of the <i>MYC</i> oncogene and downstream Myc-driven pathways. However, little is currently known about the activity of BET inhibitors in solid tumor models, and whether down-regulation of MYC family genes contributes to sensitivity. Here we provide evidence for potent BET inhibitor activity in neuroblastoma, a pediatric solid tumor associated with a high frequency of <i>MYCN</i> amplifications. We treated a panel of neuroblastoma cell lines with a novel small molecule inhibitor of BET proteins, GSK1324726A (I-BET726), and observed potent growth inhibition and cytotoxicity in most cell lines irrespective of <i>MYCN</i> copy number or expression level. Gene expression analyses in neuroblastoma cell lines suggest a role of BET inhibition in apoptosis, signaling, and N-Myc-driven pathways, including the direct suppression of <i>BCL2</i> and <i>MYCN</i>. Reversal of <i>MYCN</i> or <i>BCL2</i> suppression reduces the potency of I-BET726-induced cytotoxicity in a cell line-specific manner; however, neither factor fully accounts for I-BET726 sensitivity. Oral administration of I-BET726 to mouse xenograft models of human neuroblastoma results in tumor growth inhibition and down-regulation <i>MYCN</i> and <i>BCL2</i> expression, suggesting a potential role for these genes in tumor growth. Taken together, our data highlight the potential of BET inhibitors as novel therapeutics for neuroblastoma, and suggest that sensitivity is driven by pleiotropic effects on cell growth and apoptotic pathways in a context-specific manner.</p> </div

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses

Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Response

I-BET726: a novel selective inhibitor of BET family proteins.

<p>(<b>a</b>) Chemical structure of GSK1324726A (I-BET726). (<b>b</b>) Crystal structure of I-BET726 (magenta) bound to the acetyl-binding pocket of BRD4-BD1 (resolution: 1.6 Å). (<b>c</b>) Concentration response curves for determination of binding affinity of I-BET726 to BRD2, BRD3, and BRD4 bromodomains by ligand displacement detected using Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET). IC₅₀ values for BRD2, BRD3, and BRD4 are indicated. (<b>d</b>) Selectivity profile of I-BET726 showing average temperature shifts (delta T_m) in degrees Celsius for a panel of bromodomain proteins using a fluorescent thermal shift assay. N= 2 for all proteins except CREBBP (n= 4).</p

Global transcript profiling in neuroblastoma cell lines treated with I-BET726 reveals gene expression changes in apoptotic and signaling pathways.

<p>(<b>a</b>) Hierarchical clustering of statistically significant probes that were differentially expressed in 100 nM or 1 µM treatments of I-BET726 relative to vehicle in CHP-212 and SK–N–SH. (<b>b</b>) Venn analysis for up-regulated and down-regulated probes described in (a) in the CHP-212 cell line. (<b>c</b>) Venn analysis for overlap of up-regulated and down-regulated probes in the SK–N–SH and CHP-212 cell lines. (<b>d</b>) Functional analyses of expression changes were performed by GO and canonical pathway enrichment at the gene level. A subset of statistically significant categories for GO Biological Process (>100 genes) and canonical pathways (>20 genes) from KEGG and BioCarta that were common among the two cell lines are shown. (<b>e</b>) qRT-PCR confirmation of a subset of genes selected from the functional analyses described in (d). Data represent mean value ± standard deviation for three independent biological replicates. Asterisks indicate statistical significance as measured by t-test (p <0.05).</p

Analysis of I-BET726 activity <i>in vivo</i>.

<p>(<b>a</b>) Mean absolute body weight ± SD for mice in the SK–N-AS (left) and CHP-212 (right) xenograft studies treated with vehicle, 5 mg/kg, or 15 mg/kg I-BET726. (<b>b</b>) Mean absolute tumor volumes ± SEM for SK–N-AS subcutaneous xenografts following treatment with 5 mg/kg or 15 mg/kg I-BET726. Asterisks indicate statistical significance as measured by t-test (p <0.05). Tumor growth inhibition (TGI) for the 15 mg/kg group was 58% on day 14 (n= 9; p= 0.0060). (<b>c</b>) Mean absolute tumor volumes ± SEM for CHP-212 subcutaneous xenografts following treatment with 5 mg/kg or 15 mg/kg I-BET726. Asterisks indicate statistical significance as measured by T-test (p <0.05). TGI for 5 mg/kg was 50% on Day 42 (n= 8; p= 0.1816). TGI for 15 mg/kg was 82% on Day 42 (n=5; p =0.0488). (<b>d</b>) Pharmacodynamic analysis in CHP-212 and SK–N-AS xenografts 8 hours after initial dose of I-BET726. qRT-PCR analysis of <i>MYCN</i>, <i>MYC</i>, and <i>BCL2</i> expression following I-BET726 treatment in the indicated models. Data is presented as fold induction compared to vehicle treated controls, and represents the average ± SD of data from three animals. (<b>e</b>) qRT-PCR analysis of apoptotic pathway and N-Myc pathway genes in CHP-212 xenografts 8 hours following treatment with I-BET726 on day 8 of study. Data is presented as described in (d).</p

Suppression of <i>BCL2</i> expression by I-BET726.

<p>(<b>a</b>) Left: Concentration response curve for <i>BCL2</i> RNA expression following 24 hour treatment with I-BET726 in the CHP-212 cell line. Data was normalized to GAPDH and presented as expression relative to DMSO-treated controls. Data presented as the average of two independent curves from a single experiment, and is representative of data from two independent biological replicates. Right: Table of IC₅₀ values and percent inhibition of <i>BCL2</i> expression following 24 hour treatment with I-BET726. (<b>b</b>) BRD4 ChIP in the non-amplified neuroblastoma cell line SK–N–SH. Binding of BRD4 to the <i>BCL2</i> promoter or to an intergenic region on Chromosome 12 following treatment with vehicle or 1 µM I-BET726 for six hours. Data is presented as fold enrichment over signal generated from IgG control immunoprecipitations. Data shown was from a single experiment representative of typical results. (<b>c</b>) BRD4 ChIP data at the <i>BCL2</i> promoter, presented as percent of vehicle control signal. Data represent the mean value ± standard deviation for three independent biological replicates. Asterisk indicates statistical significance as measured by T-test (p= 0.002). (<b>d</b>) Western blot analysis of Bcl-2 expression in the <i>MYCN</i>-amplified cell lines CHP-212 and IMR32 following 48 hour treatment with vehicle or 1 µM I-BET726. Tubulin expression included as a loading control. (<b>e</b>) gIC₅₀ values obtained from CHP-212 or LA-N-2 cells overexpressing <i>GFP</i> or <i>BCL2</i> following treatment with I-BET726 in a 6 day growth-death assay. Data represents the mean value ± standard deviation from three independent experiments. (<b>f</b>) Y_min-T₀ values for CHP-212 or LA-N-2 cells overexpressing <i>GFP</i> or <i>BCL2</i>. Data represents the mean value ± standard deviation from three independent experiments. Asterisk indicates statistical significance as measured by t-test (p= 0.02). (<b>g</b>) Western blot analysis of Bcl-2 expression in CHP-212 or LA-N-2 cells overexpressing <i>GFP</i> or <i>BCL2</i> following 48 hour treatment with DMSO or 1 µM I-BET726. Actin expression included as a loading control.</p